Mission Wealth Management LP grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,426 shares of the biopharmaceutical company’s stock after purchasing an additional 6,752 shares during the quarter. Mission Wealth Management LP’s holdings in Pfizer were worth $2,337,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of PFE. Ballew Advisors Inc purchased a new position in shares of Pfizer during the 1st quarter worth $102,000. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in shares of Pfizer during the 1st quarter worth $132,000. Braun Bostich & Associates Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth $139,000. Clearwater Capital Advisors LLC acquired a new stake in shares of Pfizer during the 1st quarter worth $156,000. Finally, Goodwin Daniel L acquired a new stake in shares of Pfizer during the 2nd quarter worth $171,000. 69.01% of the stock is currently owned by institutional investors.
In related news, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the sale, the insider now directly owns 72,672 shares in the company, valued at approximately $2,979,552. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was bought at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the acquisition, the insider now owns 21,976,484 shares in the company, valued at approximately $395,576,712. The disclosure for this purchase can be found here. 0.06% of the stock is currently owned by corporate insiders.
A number of analysts have recently commented on PFE shares. Jefferies Financial Group restated a “neutral” rating and set a $39.00 price objective on shares of Pfizer in a report on Monday, July 9th. JPMorgan Chase & Co. restated a “buy” rating and set a $42.00 price objective on shares of Pfizer in a report on Wednesday, July 11th. Cantor Fitzgerald set a $45.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, July 11th. Credit Suisse Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Thursday, July 12th. Finally, Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, July 15th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average target price of $42.95.
Shares of NYSE PFE opened at $42.93 on Friday. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $45.81. The firm has a market capitalization of $255.56 billion, a P/E ratio of 16.20, a P/E/G ratio of 2.16 and a beta of 0.88. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. The firm had revenue of $13.30 billion during the quarter, compared to the consensus estimate of $13.53 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 3 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.17%. Pfizer’s dividend payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: How can you know how many shares are floating?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.